Ypsomed Partners with Novo Nordisk for Autoinjector Supply
Swiss medical technology company Ypsomed has signed a long-term supply deal with Novo Nordisk for autoinjectors, which will be used by people self-administering drugs to treat various metabolic indications. Ypsomed will manufacture autoinjectors for Novo's "second-generation GLP-1s" currently in clinical trials. The agreement comes as Novo Nordisk's weight-loss drug business is driving demand for pharmaceutical services companies. Ypsomed shares surged 5% after the announcement. The booming obesity market, estimated to be worth $100 billion by 2030, is expected to drive further demand for GLP-1 injection drugs.